Nitric oxide (NO) plays an important role in the control of the vascular tone and the most often employed NO donors have limitations due to their harmful side-effects. In this context, new NO donors have been prepared, in order to minimize such undesirable effects. cis-[Ru(bpy) 2 (py)NO 2 ](PF 6 ) (RuBPY) is a new nitrite complex synthesized in our laboratory that releases NO in the presence of the vascular tissue only. In this work the vasorelaxation induced by this NO donor has been studied and compared to that obtained with the well known NO donor SNP. The relaxation induced by RuBPY is concentration-dependent in denuded rat aortas pre-contracted with phenylephrine (EC 50 ). This new compound induced relaxation with efficacy similar to that of SNP, although its potency is lower. The time elapsed until maximum relaxation is achieved (E max = 240 s) is similar to measured for SNP (210 s). Vascular reactivity experiments demonstrated that aortic relaxation by RuBPY is inhibited by the soluble guanylyl-cyclase inhibitor 1H-[1,2,4] oxadiozolo[4,3-a]quinoxaline-1-one (ODQ 1 lM). In a similar way, 1 lM ODQ also reduces NO release from the complex as measured with DAF-2 DA by confocal microscopy. These findings suggest that this new complex RuBPY that has nitrite in its structure releases NO inside the vascular smooth muscle cell. This ruthenium complex releases significant amounts of NO only in the presence of the aortic tissue. Reduction of nitrite to NO is most probably dependent on the soluble guanylyl-cyclase enzyme, since NO release is inhibited by ODQ.
Introduction
The endogenous production of nitric oxide (NO) is a key step in the control of the vascular tone [1] . Moreover, it plays an important role in a variety of physiological and pathological processes such as neurotransmission, blood pressure control, inhibition of platelet aggregation, and immunological responses in different cells and tissues [2] [3] [4] . Perhaps the most extensively studied process involving NO is related to vascular relaxation, in which variations in the NO concentration are attributed to decreasing cytosolic Ca 2+ levels [5, 6] . NO-induced vascular relaxation occurs by stimulating the production of guanosine 3 0 ,5 0 -cyclic monophosphate (cGMP) via soluble guanylyl-cyclase (sGC) activation [7] and/or by causing membrane hyperpolarization via K + channel activation [8] .
Despite the great importance of NO in biological systems, its pharmacological studies have been limited due to its high reactivity and short half-life [9, 10] . The free radical nature of NO has hindered the understanding of many problems associated with its diffusion delay or associated with the effect that NO presents on its action targets [11, 12] . One compound commonly used as NO-delivery agent in pharmacological and clinical studies is the sodium nitroprusside salt (SNP) {Na 2 [Fe(CN) 5 NO]} [13, 14] . However, SNP is potentially dangerous owing to side reactions involving cyanide (CN À ) release as part of the reduction process [14, 15] , and this poses an important limitation to its pharmacological use [16] . In this context, the development of new molecules that deliver NO under controlled conditions can be a valuable tool for the understanding of its biological mechanism and could constitute a new class of therapeutic agents [17, 18] . Nitrosyl ruthenium complexes have been postulated as a new class of NO-delivery agents [19] based on reduction process, tissue-enzymatic action [14] [15] [16] or through light irradiation [20] . Despite the well-established pharmacological process of these ruthenium species, their stability is dependent on pH, because their conversion to nitro-ruthenium species (Eq. (1)) apparently yields a compound that is a less potent NO-donor agent [21] . This somehow limits the use of these species in therapeutic evaluations [22] .
Until recently, nitrite was considered an end-product of NO metabolism. However, several studies support evidence that nitrite metabolism occurs in the tissues and blood to form NO [23] . In fact, nitrite can be considered the largest intravascular storage pool for NO [24] . Various studies have emphasized the possible therapeutic role of nitrite in the treatment and prevention of cardiovascular diseases such as hypertension [25] . Several ruthenium-derived compounds have been synthesized in our laboratory [19] ; however, only the complex cis-[Ru(bpy) 2 (py)NO 2 ](PF 6 ) (RuBPY) contains nitrite that can be converted to NO.
During physiological and pathological hypoxia, nitrite is converted to NO via reactions with hemoglobin, myoglobin, xanthine oxidoreductase, and heme-and tiol-containing enzymes, and by acidic disproportionation [26] . Vasodilatation induced by nitrite has been reported to occur after infusion of sodium nitrite into the forearm brachial artery of healthy volunteers, which increased blood flow and produced substantial vasodilatation [24] . The nitrite reductase activity of deoxyhemoglobin is a major mechanism of NO generation from nitrite [27] , and it may be involved in hypoxic vasodilation. As reported by Alzawahra et al. [28] nitrite can be reduced to NO by heme proteins such as sGC, which in turn can be inhibited by ODQ. Several new metal complexes have been studied as a new class of NO donors [29] , including nitrosyl ruthenium complexes. Some of these complexes exhibit low toxicity and are quite soluble in aqueous solutions. Our new nitrite ruthenium NO donor RuBPY contains nitrite in its molecule, which makes this NO donor different from others studied in our laboratory [30] [31] [32] .
Considering the chemical characteristics of the RuBPY complex, the aim of the present work was to study the effect of this nitrite ruthenium NO-donor complex as a pro-drug that could release NO only upon induction. The vasorelaxation induced by this inorganic NO donor was thus studied, and its effects were compared to those obtained with the well known NO donor SNP.
Materials and methods

Synthesis of cis-[Ru(bpy) 2 (py)NO 2 ](PF 6 ) (RuBPY)
The RuBPY complex was synthesized as previously reported and was characterized by UV-Visible spectroscopy as well as cyclic voltammetry experiments [33] .
Amperometric determination of NO release from the NO donor
The NO measurements were performed by using the ISO-NO NOmeter and DUO-18 acquisition board. The sensitivity of this apparatus ranges from 1 nM to 20 lM, with a 2 mm sensor, which directly detects NO by amperometric technique. The setup was calibrated following a previously reported procedure [34] [35] [36] . NO released from 100 lM RuBPY in Krebs salt solution was measured in the absence or in the presence of phenylephrine or in the presence of the aortic ring. All the experiments were performed at room light.
Confocal microscopy
In order to image arterial cross-sections, the rings (100 lm thick) were placed vertically in a glass slide covered with poly-L-lysine. The tissue was loaded with the fluorescent NO dye, diaminofluorescein-2 diacetate (10 lM DAF-2 DA), in the normal Hanks solution for 40 min at room temperature [37] . After washing, the segment was placed in a chamber (1 mL in volume) that was placed on the stage of the confocal scanning laser microscope (Leica TCS SP2) and viewed from the bottom of the chamber through a water-immersion objective (63Â). Images of the aortic ring segment were sequentially taken every 2 s in Hanks buffer (pH 7.4) with the following composition (mM): NaCl 145, KCl 5.0, NaH 2-PO 4 ÁH 2 O 0.5, MgCl 2 Á6H 2 O 1.0, glucose 10.0, CaCl 2 1.6, and Hepes 10.0. The cytosolic NO concentration ([NO] c ) was assessed by exciting the DAF-2 DA fluorophore with the 488 nm line of an argon ion laser and measuring the fluorescence at 515 nm. A time-course software was used to capture images of the cells at intervals of 2 s (xyt) in the Live Data Mode acquisition at 512 Â 512 pixel resolution, at 400 Hz. The protocol was designed to measure [NO] c in denuded slices of rat aorta. [NO] c was measured in the vascular smooth muscle before and after addition of 3 lM RuBPY in the presence or absence of 1 lM sGC inhibitor [1H- [1, 2, 4] oxadiazolo-[4,3-a]quinoxalin-1-one] (ODQ). By applying the computer software of the LSCM, the intensities of intracellular maximum or minimum fluorescence were measured. In this way, the difference in fluorescence intensity (DFI) between the basal spectrum (F 0 ) and the spectrum recorded after addition of the NO donor (F) reflects the increase in [NO] c , which was calculated by the formula: DFI = (F À F 0 ). The fluorescence signal used to calculate [NO] c was measured in a area of aortic smooth muscle tissue and averaged.
Aortic ring preparations
The pharmacological studies were performed in accordance with the Ethical Animal Committee of the University of São Paulo (07.1.608.53.8 Campus of Ribeirão Preto).
Male Wistar rats (180-200 g) were killed by decapitation under anesthesia. The thoracic aorta was quickly removed, dissected free, and cut into 4 mm-long rings. The endothelium was mechanically removed by gently rolling the lumen of the vessel on a thin wire. The aortic rings were placed between two stainless-steel stirrups and connected to an isometric force transducer (Letica Scientific Instruments, Barcelona, Spain), to measure the tension. The rings were placed in a 10 mL organ chamber containing Krebs solution with the following composition (mM): NaCl 130, KCl 4.7, KH 2 PO 4 1.2, MgSO 4 1.2, NaHCO 3 14.9, glucose 5.5, and CaCl 2 1.6. The solution was maintained at pH 7.4 and gassed with 95% O 2 and 5% CO 2 , at 37°C. After an equilibration period of 60 min., under resting tension of 1.5 g, the aortic rings were continuously stimulated with 0.1 lM phenylephrine, which is the concentration that produced half-maximal contraction (EC 50 ) until reproducible contractile responses were obtained. All experiments were performed on endotheliumdenuded aortic rings. The absence of endothelium was confirmed by the lack of relaxation response to 1 lM acetylcholine in the presence of contractile tone induced by phenylephrine. Since our studies require endothelium-denuded aortas, the rings were discharged if there was any degree of relaxation to acetylcholine, in order to avoid possible influence from endothelial factors. After the equilibration period, specific protocols were performed in rat aortic rings.
Experimental protocols
Relaxation induced by RuBPY and SNP in arteries pre-contracted with phenylephrine
Aortic rings were pre-contracted with phenylephrine (PE, 0.1 lM). When the contraction to phenylephrine had reached a plateau, RuBPY (3 nM-5 lM) or SNP (0.1 nM-0.1 lM) was cumulatively added.
Time-course for the relaxation induced by RuBPY and SNP
In order to study the kinetics of the vasorelaxation effect, the NO donors were added to the organ chamber when a stable contraction in response to 0.1 lM phenylephrine was achieved. The NO donors were added at the concentration that induced maximum relaxation, i.e., 3 lM RuBPY or 0.1 lM SNP. The time-course for the relaxation induced by these compounds was evaluated.
Relaxation induced by RuBPY and SNP in arteries pre-contracted with 60 mM KCl
Aortic rings were pre-contracted with highly concentrated KCl solution (60 mM), and cumulative concentration-response curves were constructed for RuBPY (3 nM-5 lM) or SNP (0.1 nM-0.1 lM).
Effect of the soluble guanylyl-cyclase inhibitor ODQ on the relaxation induced by RuBPY and SNP
In order to verify whether the vasodilatation induced by the new NO donor RuBPY is due to guanylyl-cyclase activation, the selective sGC inhibitor ODQ (1 lM) was added 30 min before the addition of phenylephrine (0.1 lM). Subsequently, cumulative concentration-response curves for RuBPY and SNP were constructed in the presence of ODQ.
Effect of the inhibition of phosphodiesterase on the relaxation induced by RuBPY and SNP
In order to verify whether cGMP is involved in the relaxation of aortic rings by RuBPY and SNP, the selective inhibitor of type V phosphodiesterase (PDE), dipyridamole (1 lM) was added 30 min before the addition of phenylephrine (0.1 lM). Subsequently, 
Drugs and solutions
Acetylcholine, phenylephrine, ODQ, sodium nitroprusside (SNP), dipyridamole and DAF-2 DA were purchased from Sigma Chemical Co. (St. Louis, MO-USA). Acetylcholine, SNP, and phenylephrine were diluted in deionized water. RuBPY solutions were prepared in pH 7.4 phosphate buffer (1 mM). ODQ and dipyridamole were diluted in dimethylsulfoxide. DAF-2 DA was prepared in Hanks physiological solution.
Data and statistical analysis
Relaxation responses to the NO donor were measured from the plateau of the phenylephrine contraction and were expressed as percent reversal of the phenylephrine pre-contraction. Individual relaxation curves were fitted to a sigmoidal logistic equation (Graphpad Prism 3.0); pD 2 values (pEC 50 ) were calculated and expressed as Àlog [M]. The maximum effect (E max ) was considered as the maximal amplitude response reached in the concentration-effect curves for the relaxant agent. In each set of experiments, n indicates the number of studied rats. Differences between mean pD 2 and E max values were both assessed by one-way analysis of variance (ANOVA) followed by a Newman-Keuls post-hoc test. Unpaired student's t test was used to analyze the microscopy data. Results are expressed as mean ± SEM, and statistical significance was accepted at a level of P < 0.05.
Results
Determination of NO release from the NO donor
According to the electronic spectroscopy analysis, the nitrite ruthenium complex RuBPY is stable in aqueous solution, at room temperature, for at least 10 days. Similarly, RuBPY does not exhibit any appreciable photoreactivity under visible light irradiation. However, chronoamperograms performed with RuBPY in physiological solution in the presence of aortic tissue, using an NO-sensor, revealed a typical pattern derived from an NO-donor agent (Fig. 1) , which was not observed when the experiment was developed with the vehicle only, the NO donor only, or the NO donor in the presence of phenylephrine.
Confocal microscopy
NO measurement in the cell milieu was also accomplished by confocal microscopy (Fig. 2) . Nitric oxide was quantified by mea-suring the fluorescence intensity (FI) by using fluorescent dye DAF-2 DA that intracellularly is converted to DAF-2T. The cytosolic NO concentration ([NO] c ) in the vascular smooth muscle of aortic rings was obtained in the absence of the complex and after addition of RuBPY. In the latter case, the basal [NO] C was significantly increased in DFI: 1645.14 ± 388.30 (n = 5). As for the aortic rings pre-incubated with ODQ, the fluorescence was lower DFI: 366.88 ± 120.3 (n = 7, P < 0.01) than that achieved in the aortic tissue in the absence of ODQ, as depicted in Fig. 2C .
Relaxation induced by RuBPY and SNP in arteries pre-contracted with phenylephrine
The relaxations induced by both NO donors RuBPY and SNP in denuded rat aortas pre-contracted with 0.1 lM phenylephrine were concentration-dependent. Although the maximum effect (E max ) was similar for SNP (101.2 ± 2.8%, n = 5) and RuBPY (104.4 ± 1.1%, n = 5), the potency of SNP (pD 2 : 8.25 ± 0.12, n = 5) was greater than the potency of RuBPY (pD 2 : 6.54 ± 0.07, n = 5, P < 0.001) with respect to induction of aortic rings relaxation ( Fig. 3) .
Time-course for the relaxation induced by RuBPY and SNP
As shown in Fig. 4 , the use of NO donor concentrations that yield maximum relaxation demonstrates that the SNP and RuBPY complexes present similar time-course, with maximum relaxation occurring at 210 and 240 s, respectively.
Relaxation induced by RuBPY and SNP in arteries pre-contracted with 60 mM KCl
Vascular reactivity studies revealed that the complex does not require chemical reduction to release NO and promote vasodilatation. In aortic rings pre-contracted with 60 mM KCl, the maximum effect was lower (60.2 ± 3.5%, n = 6, P < 0.001) than that obtained in phenylephrine pre-contracted arteries (104.9 ± 1.1%, n = 5) ( Fig. 5 ). Similar results were found for SNP that had its vasodilatation reduced from 101.2 ± 2.8% to 44.0 ± 1.8%; n = 5 (P < 0.001).
Effect of the soluble guanylyl-cyclase inhibitor ODQ on the relaxation induced by RuBPY and SNP
Our studies also evidenced that NO released from the RuBPY complex induces vasodilatation by activation of sGC. Indeed, the selective sGC inhibitor ODQ reduced the maximum relaxation of the compound RuBPY from 104.4 ± 1.1% to 38.0 ± 3.6% (n = 8, P < 0.001), as shown in Fig. 6 . Similar results were found for SNP where the vasodilatation was reduced from 101.2 ± 2.8% to 29.3 ± 2.6%; n = 5 (P < 0.001) in the presence of ODQ.
Effect of inhibition of phosphodiesterase (PDE) on the relaxation induced by RuBPY and SNP
Vascular reactivity studies revealed that the vasodilatation induced by RuBPY was potentiated when PDE-V was inhibited with dipyridamole. The pD 2 values increased from 6.54 ± 0.07 (n = 5) to 6.99 ± 0.09, (n = 5), P < 0.05 ( Fig. 7) . We also found similar results for SNP that had higher potency in the presence of PDE inhibitor (pD 2 : from 8.25 ± 0.12 (n = 5) to 8.96 ± 0.15 (n = 6), P < 0.001.
Discussion
Although some nitrosyl ruthenium complexes have been reported to be NO-delivery agents, numerous species are unstable in physiological conditions or give rise to side-reactions that lead to different products in addition to NO [22, 38, 39] . We have found that RuBPY can function as an NO-delivery agent spontaneously after crossing the membrane barrier. On the basis of electronic spectroscopy analysis, the nitrite ruthenium species is stable for a long period in aqueous solution, at physiological pH. In contrast to other nitrosyl complexes previously studied in our laboratory RuBPY does not release NO under visible light irradiation or by a reducing electrolytic process.
The investigation of the induced NO-releasing pathway was supported by in situ NO detection when an aqueous phosphate buf-fer solution of RuBPY was submitted to the action of phenylephrine in the presence of the aortic tissue or room light. The increase in current, which is proportional to the NO concentration, is negligible. Nevertheless, in the presence of the aortic tissue, NO is released from RuBPY with a typical pattern of NO release (Fig. 1) . These results indicate that RuBPY does not need to be chemically reduced to deliver NO, because NO is not released in the presence of the reducing agent phenylephrine. On the other hand, NO release is tissue-dependent. These data differ from results reported for other ruthenium compounds capable of donating NO, which only deliver NO upon stimulation [40] . In the present study, the NO concentration in the smooth muscle of aortic rings was also determined by using the NO sensitive dye, namely DAF-2 DA. This dye reacts with N 2 O 3 present in the cell cytosol. The formation of N 2 O 3 requires two molecules of NO. Therefore, the stoichiometry of the reaction between DAF-2DA and NO is 1:2, which means that DAF does not directly react with NO, but it reacts with the oxidized form of NO [41] . It was observed that the NO concentration is significantly enhanced after RuBPY addition. Considering that NO was measured in denuded aortic rings, the enhanced fluorescence from the bound DAF can be attributed to NO release from RuBPY. In the same experiment, it was demonstrated that in presence of a sGC inhibitor ODQ, the fluorescence of the dye was lower than that measured in the preparation without ODQ. These results suggest that enzymes that can be inhibited by ODQ as the soluble guanylyl-cyclase, are responsible for conversion of nitrite present in the compound to nitric oxide [28] .
The new NO donor RuBPY induces relaxation in aortic rings precontracted with phenylephrine in a concentration-dependent manner, although its potency is lower than that of SNP. Thus, a higher concentration of RuBPY was necessary to induce 50% of maximum effect as compared to SNP. These results are in accordance to Bonaventura et al. [32] that have reported a higher potency of SNP as compared to another nitrosyl complex. SNP is well-known to be a rapid and efficient nitrovasodilator compound [42] that is therapeutically used in hypertensive emergencies. SNP is thought to exert its vasodilator action, at least in part, by NO release into the vascular smooth muscle cell. In our experiments, the maximum relaxation was reached with 0.1 lM SNP and 3 lM RuB-PY ( Fig. 3 ). However, both NO donors presented similar efficacy in relaxing the rat aorta. Similar experiments were performed by using sodium nitrite [28] and, in this work, the authors used 2 mM NO donor to reach 100% vasodilatation, which is 1000 times more concentrated than the RuBPY concentrations reported here to have equivalent effects. If similar vasorelaxation mechanisms are proposed for both nitrite species, it can be inferred that the nitrite ruthenium complex favors the mechanism involved in NO generation.
The time required for achievement of the complete concentration-effect curve for relaxation with RuBPY is not significantly different from that found in the case of SNP once the concentrations were adjusted in account for the difference of efficacy. In the pulmonary arteries of male piglets, Lopez-Lopez et al. [42] have reported that the time-course of relaxation to a single concentration of SNP (3 lM) was 220 s. The differences between our results and those observed by Lopez-Lopez et al. [42] are insignificant but the concentrations of SNP used were different, it may be related to vascular bed or animal species.
In the present study, we have compared the cellular mechanisms of vasodilatation induced by our compound and with SNP. To investigate whether the ruthenium complex requires chemical reduction to promotes vasodilatation, we have constructed concentration-response curves for RuBPY in the absence of the reducing agent phenylephrine. The preparations were pre-contracted with KCl, in which the contractile response is not mediated by receptors but by cell membrane depolarization, thereby resulting in the opening of voltage-dependent calcium channels [43] .
Since the relaxation induced by RuBPY is diminished but not abolished by addition of a high concentration of KCl to the extracellular medium, the hypothesis that K + channel activation is important for RuBPY relaxation could be proposed, but this is not the only mechanism involved in the rat aorta relaxation induced by this NO donor. We have found similar results to SNP that had its relaxation decreased but not abolished. Our results demonstrated that SNP can release NO by other ways else chemical reduction by photochemical release and decomposition in presence of vascular tissue as reported by Bates et al. [14] .
NO induces vascular smooth muscle relaxation through the activation of sGC, hence converting GTP to cGMP, which acts as a second messenger activating PKG. The latter, in turn, phosphorylates various proteins, producing vasorelaxation [44] . The increase in cGMP levels and the consequent activation of PKG reduces cyto- solic calcium concentrations by different mechanisms such as K + channel activation and inhibition of L-type Ca +2 channels [45] or direct activation of K + channels by NO [8] . On the basis of these mechanisms activated by NO, another purpose of the present study was to characterize the vascular effects of this NO donor by using pharmacological tools like sGC inhibitors.
ODQ, a selective inhibitor of sGC [46] , was employed for verification of the role of this enzyme in the relaxation cascade induced by RuBPY. The inhibitory effect of ODQ is due to changes in the oxidation state of the heme moiety without adverse effects on the catalytic activity of the enzyme. Although ODQ has been reported to interfere with heme-protein-dependent process [47] , it remains the most selective and potent inhibitor available for soluble guanylyl-cyclase. Sensitivity toward ODQ inhibition of vascular relaxation would indicate a predominant mechanism of heme sitemediated activation of sGC, whereas resistance toward ODQ would suggest the possible presence of alternative mechanisms of vasorelaxation. Our results have shown that the relaxation induced by RuBPY or SNP are partially inhibited by ODQ. These results suggest that these NO donors can elicit vascular relaxation, at least in part, through a secondary pathway that is independent of the activation of the heme site of sGC.
In the present study we have observed the effect of type 5 cGMP-PDE inhibition on the vasodilatation induced by RuBPY and SNP. The predominant PDE isoenzymes present in human smooth muscle and endothelial cells are PDE1 and PDE5, and dipyridamole selectively inhibits the latter. Dipyridamole, therefore, could act by potentiating the actions of those mediators that work through cGMP, such as nitric oxide [48] . In the relaxation response induced by RuBPY or SNP, dipyridamole produced a leftward shift of the concentration-response curve. These results provide evidence for the effect of cGMP in the vasodilatation induced by the NO donors RuBPY and SNP.
Taken together, the present findings demonstrate that the new complex RuBPY has its nitrite converted into NO, and that this process appears to be catalyzed by soluble guanylyl-cyclase enzyme sensitive to ODQ. The RuBPY complex induces vascular relaxation that is as fast as that promoted by SNP. Our results demonstrated that the mechanisms of relaxation by RuBPY are similar to SNP with high participation of sGC-cGMP.
